Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2010

01.07.2010 | Preclinical study

A hypersensitive estrogen receptor α mutation that alters dynamic protein interactions

verfasst von: Matthew H. Herynk, Torsten Hopp, Yukun Cui, Airu Niu, Arnoldo Corona-Rodriguez, Suzanne A. W. Fuqua

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Estrogen receptor α (ERα) is highly regulated through multiple mechanisms including cell signaling, posttranslational modifications, and protein–protein interactions. We have previously identified a K303R ERα mutation within the hinge region of ERα. This mutation results in an altered posttranslational regulation and increased in vitro growth in the presence of low estrogen concentrations. We sought to determine if cells expressing this mutant ERα would display hypersensitive tumor growth in in vivo athymic ovariectomized nude mice. MCF-7 cells, stably expressing the K303R ERα, formed tumors in nude mice faster than cells expressing wild-type ERα in the presence of low levels of estrogen. When estrogen was withdrawn, all tumors regressed but half of the K303R ERα-expressing tumors became estrogen-independent and regrew. We evaluated potential mechanisms for the observed hypersensitivity. The mutant ERα did not demonstrate increased estrogen binding affinity, but did exhibit increased interactions with members of the SRC family of coactivators. The mutant ERα demonstrated increased levels and occupancy time on the pS2 promoter. In the presence of the K303R ERα, the SRC-3 and p300 coactivators also displayed increased levels and time on the pS2 promoter. The K303R ERα has, in part, lost critical negative regulation by the F domain. Collectively, these data demonstrate an important role for the K303R ERα mutation in hormonal regulation of tumor growth and estrogen-regulated promoter dynamics in human breast cancer.
Literatur
1.
Zurück zum Zitat Clarke R, Brunner N, Katzenellenbogen BS, Thompson EW, Norman MJ, Koppi C, Paik S, Lippman ME, Dickson RB (1989) Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc Natl Acad Sci USA 86:3649–3653CrossRefPubMedPubMedCentral Clarke R, Brunner N, Katzenellenbogen BS, Thompson EW, Norman MJ, Koppi C, Paik S, Lippman ME, Dickson RB (1989) Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc Natl Acad Sci USA 86:3649–3653CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y (1987) Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 47:4355–4360PubMed Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y (1987) Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 47:4355–4360PubMed
3.
Zurück zum Zitat Welshons WV, Jordan VC (1987) Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur J Cancer Clin Oncol 23:1935–1939CrossRefPubMed Welshons WV, Jordan VC (1987) Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur J Cancer Clin Oncol 23:1935–1939CrossRefPubMed
4.
Zurück zum Zitat Shim WS, Conaway M, Masamura S, Yue W, Wang JP, Kmar R, Santen RJ (2000) Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 141:396–405PubMed Shim WS, Conaway M, Masamura S, Yue W, Wang JP, Kmar R, Santen RJ (2000) Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 141:396–405PubMed
5.
Zurück zum Zitat Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O’Connell P, Allred DC (2000) A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res 60:4026–4029PubMed Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O’Connell P, Allred DC (2000) A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res 60:4026–4029PubMed
6.
Zurück zum Zitat Pakdel F, Reese JC, Katzenellenbogen BS (1993) Identification of charged residues in an N-terminal portion of the hormone-binding domain of the human estrogen receptor important in transcriptional activity of the receptor. Mol Endocrinol 7:1408–1417PubMed Pakdel F, Reese JC, Katzenellenbogen BS (1993) Identification of charged residues in an N-terminal portion of the hormone-binding domain of the human estrogen receptor important in transcriptional activity of the receptor. Mol Endocrinol 7:1408–1417PubMed
7.
Zurück zum Zitat Rayala SK, Talukder AH, Balasenthil S, Tharakan R, Barnes CJ, Wang RA, Aldaz M, Khan S, Kumar R (2006) P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res 66:1694–1701CrossRefPubMed Rayala SK, Talukder AH, Balasenthil S, Tharakan R, Barnes CJ, Wang RA, Aldaz M, Khan S, Kumar R (2006) P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res 66:1694–1701CrossRefPubMed
8.
Zurück zum Zitat Al-Dhaheri MH, Rowan BG (2006) PKA exhibits selective modulation of estradiol dependent transcription in breast cancer cells that is associated with decreased ligand binding, altered ER{alpha} promoter interaction and changes in receptor phosphorylation. Mol Endocrinol 21:439–456CrossRefPubMed Al-Dhaheri MH, Rowan BG (2006) PKA exhibits selective modulation of estradiol dependent transcription in breast cancer cells that is associated with decreased ligand binding, altered ER{alpha} promoter interaction and changes in receptor phosphorylation. Mol Endocrinol 21:439–456CrossRefPubMed
9.
Zurück zum Zitat Wang RA, Mazumdar A, Vadlamudi RK, Kumar R (2002) P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J 21:5437–5447CrossRefPubMedPubMedCentral Wang RA, Mazumdar A, Vadlamudi RK, Kumar R (2002) P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J 21:5437–5447CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Cui Y, Zhang M, Pestell R, Curran EM, Welshons WV, Fuqua SA (2004) Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity. Cancer Res 64:9199–9208CrossRefPubMed Cui Y, Zhang M, Pestell R, Curran EM, Welshons WV, Fuqua SA (2004) Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity. Cancer Res 64:9199–9208CrossRefPubMed
11.
Zurück zum Zitat Balasenthil S, Barnes CJ, Rayala SK, Kumar R (2004) Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells. FEBS Lett 567:243–247CrossRefPubMed Balasenthil S, Barnes CJ, Rayala SK, Kumar R (2004) Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells. FEBS Lett 567:243–247CrossRefPubMed
12.
Zurück zum Zitat Mishra SK, Mazumdar A, Vadlamudi RK, Li F, Wang RA, Yu W, Jordan VC, Santen RJ, Kumar R (2003) MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions. J Biol Chem 278:19209–19219CrossRefPubMed Mishra SK, Mazumdar A, Vadlamudi RK, Li F, Wang RA, Yu W, Jordan VC, Santen RJ, Kumar R (2003) MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions. J Biol Chem 278:19209–19219CrossRefPubMed
13.
Zurück zum Zitat Cui Y, Niu A, Pestell R, Kumar R, Curran EM, Liu Y, Fuqua SA (2006) Metastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cells. Mol Endocrinol 20:2020–2035CrossRefPubMedPubMedCentral Cui Y, Niu A, Pestell R, Kumar R, Curran EM, Liu Y, Fuqua SA (2006) Metastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cells. Mol Endocrinol 20:2020–2035CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J, Gannon F (2003) Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 11:695–707CrossRefPubMed Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J, Gannon F (2003) Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 11:695–707CrossRefPubMed
15.
Zurück zum Zitat Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M (2000) Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843–852CrossRefPubMed Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M (2000) Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843–852CrossRefPubMed
16.
Zurück zum Zitat Shao W, Keeton EK, McDonnell DP, Brown M (2004) Coactivator AIB1 links estrogen receptor transcriptional activity and stability. Proc Natl Acad Sci USA 101:11599–11604CrossRefPubMedPubMedCentral Shao W, Keeton EK, McDonnell DP, Brown M (2004) Coactivator AIB1 links estrogen receptor transcriptional activity and stability. Proc Natl Acad Sci USA 101:11599–11604CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Onate SA, Tsai SY, Tsai MJ, O’Malley BW (1995) Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354–1357CrossRefPubMed Onate SA, Tsai SY, Tsai MJ, O’Malley BW (1995) Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354–1357CrossRefPubMed
18.
Zurück zum Zitat Voegel JJ, Heine MJ, Zechel C, Chambon P, Gronemeyer H (1996) TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 15:3667–3675PubMedPubMedCentral Voegel JJ, Heine MJ, Zechel C, Chambon P, Gronemeyer H (1996) TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 15:3667–3675PubMedPubMedCentral
19.
Zurück zum Zitat Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965–968CrossRefPubMed Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965–968CrossRefPubMed
20.
Zurück zum Zitat Baniahmad A, Ha I, Reinberg D, Tsai S, Tsai MJ, O’Malley BW (1993) Interaction of human thyroid hormone receptor beta with transcription factor TFIIB may mediate target gene derepression and activation by thyroid hormone. Proc Natl Acad Sci USA 90:8832–8836CrossRefPubMedPubMedCentral Baniahmad A, Ha I, Reinberg D, Tsai S, Tsai MJ, O’Malley BW (1993) Interaction of human thyroid hormone receptor beta with transcription factor TFIIB may mediate target gene derepression and activation by thyroid hormone. Proc Natl Acad Sci USA 90:8832–8836CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Herynk MH, Beyer AR, Cui Y, Weiss H, Anderson E, Green TP, Fuqua SA (2006) Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol Cancer Ther 5:3023–3031CrossRefPubMed Herynk MH, Beyer AR, Cui Y, Weiss H, Anderson E, Green TP, Fuqua SA (2006) Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol Cancer Ther 5:3023–3031CrossRefPubMed
22.
Zurück zum Zitat Masamura S, Santner SJ, Heitjan DF, Santen RJ (1995) Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 80:2918–2925PubMed Masamura S, Santner SJ, Heitjan DF, Santen RJ (1995) Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 80:2918–2925PubMed
23.
Zurück zum Zitat Ding XF, Anderson CM, Ma H, Hong H, Uht RM, Kushner PJ, Stallcup MR (1998) Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. Mol Endocrinol 12:302–313CrossRefPubMed Ding XF, Anderson CM, Ma H, Hong H, Uht RM, Kushner PJ, Stallcup MR (1998) Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. Mol Endocrinol 12:302–313CrossRefPubMed
24.
Zurück zum Zitat Oesterreich S, Zhang Q, Hopp T, Fuqua SA, Michaelis M, Zhao HH, Davie JR, Osborne CK, Lee AV (2000) Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. Mol Endocrinol 14:369–381CrossRefPubMed Oesterreich S, Zhang Q, Hopp T, Fuqua SA, Michaelis M, Zhao HH, Davie JR, Osborne CK, Lee AV (2000) Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. Mol Endocrinol 14:369–381CrossRefPubMed
25.
Zurück zum Zitat Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926–935CrossRefPubMed Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926–935CrossRefPubMed
26.
Zurück zum Zitat Carlson KE, Choi I, Gee A, Katzenellenbogen BS, Katzenellenbogen JA (1997) Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry 36:14897–14905CrossRefPubMed Carlson KE, Choi I, Gee A, Katzenellenbogen BS, Katzenellenbogen JA (1997) Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry 36:14897–14905CrossRefPubMed
27.
Zurück zum Zitat Jiang W, Nordeen SK, Kadonaga JT (2000) Transcriptional analysis of chromatin assembled with purified ACF and dNAP1 reveals that acetyl-CoA is required for preinitiation complex assembly. J Biol Chem 275:39819–39822CrossRefPubMed Jiang W, Nordeen SK, Kadonaga JT (2000) Transcriptional analysis of chromatin assembled with purified ACF and dNAP1 reveals that acetyl-CoA is required for preinitiation complex assembly. J Biol Chem 275:39819–39822CrossRefPubMed
28.
Zurück zum Zitat Ing NH, Beekman JM, Tsai SY, Tsai MJ, O’Malley BW (1992) Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II). J Biol Chem 267:17617–17623PubMed Ing NH, Beekman JM, Tsai SY, Tsai MJ, O’Malley BW (1992) Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II). J Biol Chem 267:17617–17623PubMed
29.
Zurück zum Zitat Jacq X, Brou C, Lutz Y, Davidson I, Chambon P, Tora L (1994) Human TAFII30 is present in a distinct TFIID complex and is required for transcriptional activation by the estrogen receptor. Cell 79:107–117CrossRefPubMed Jacq X, Brou C, Lutz Y, Davidson I, Chambon P, Tora L (1994) Human TAFII30 is present in a distinct TFIID complex and is required for transcriptional activation by the estrogen receptor. Cell 79:107–117CrossRefPubMed
30.
Zurück zum Zitat Chambraud B, Berry M, Redeuilh G, Chambon P, Baulieu EE (1990) Several regions of human estrogen receptor are involved in the formation of receptor-heat shock protein 90 complexes. J Biol Chem 265:20686–20691PubMed Chambraud B, Berry M, Redeuilh G, Chambon P, Baulieu EE (1990) Several regions of human estrogen receptor are involved in the formation of receptor-heat shock protein 90 complexes. J Biol Chem 265:20686–20691PubMed
31.
Zurück zum Zitat Scherrer LC, Picard D, Massa E, Harmon JM, Simons SS Jr, Yamamoto KR, Pratt WB (1993) Evidence that the hormone binding domain of steroid receptors confers hormonal control on chimeric proteins by determining their hormone-regulated binding to heat-shock protein 90. Biochemistry 32:5381–5386CrossRefPubMed Scherrer LC, Picard D, Massa E, Harmon JM, Simons SS Jr, Yamamoto KR, Pratt WB (1993) Evidence that the hormone binding domain of steroid receptors confers hormonal control on chimeric proteins by determining their hormone-regulated binding to heat-shock protein 90. Biochemistry 32:5381–5386CrossRefPubMed
32.
Zurück zum Zitat Koide A, Zhao C, Naganuma M, Abrams J, Deighton-Collins S, Skafar DF, Koide S (2006) Identification of regions within the F domain of the human estrogen receptor-alpha important for modulating transactivation and protein–protein interactions. Mol Endocrinol 21:829–842CrossRefPubMed Koide A, Zhao C, Naganuma M, Abrams J, Deighton-Collins S, Skafar DF, Koide S (2006) Identification of regions within the F domain of the human estrogen receptor-alpha important for modulating transactivation and protein–protein interactions. Mol Endocrinol 21:829–842CrossRefPubMed
33.
Zurück zum Zitat Richards J, Miller M, Abend J, Koide A, Koide S, Dewhurst S (2003) Engineered fibronectin type III domain with a RGDWXE sequence binds with enhanced affinity and specificity to human alphavbeta3 integrin. J Mol Biol 326:1475–1488CrossRefPubMed Richards J, Miller M, Abend J, Koide A, Koide S, Dewhurst S (2003) Engineered fibronectin type III domain with a RGDWXE sequence binds with enhanced affinity and specificity to human alphavbeta3 integrin. J Mol Biol 326:1475–1488CrossRefPubMed
34.
Zurück zum Zitat Koide A, Zhao C, Naganuma M, Abrams J, Deighton-Collins S, Skafar DF, Koide S (2007) Identification of regions within the F domain of the human estrogen receptor-alpha important for modulating transactivation and protein–protein interactions. Mol Endocrinol 21:829–842CrossRefPubMed Koide A, Zhao C, Naganuma M, Abrams J, Deighton-Collins S, Skafar DF, Koide S (2007) Identification of regions within the F domain of the human estrogen receptor-alpha important for modulating transactivation and protein–protein interactions. Mol Endocrinol 21:829–842CrossRefPubMed
35.
Zurück zum Zitat Sentis S, Le Romancer M, Bianchin C, Rostan MC, Corbo L (2005) Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol Endocrinol 19:2671–2684CrossRefPubMed Sentis S, Le Romancer M, Bianchin C, Rostan MC, Corbo L (2005) Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol Endocrinol 19:2671–2684CrossRefPubMed
36.
Zurück zum Zitat Skafar DF, Koide S (2006) Understanding the human estrogen receptor-alpha using targeted mutagenesis. Mol Cell Endocrinol 246:83–90CrossRefPubMed Skafar DF, Koide S (2006) Understanding the human estrogen receptor-alpha using targeted mutagenesis. Mol Cell Endocrinol 246:83–90CrossRefPubMed
37.
Zurück zum Zitat Peters GA, Khan SA (1999) Estrogen receptor domains E and F: role in dimerization and interaction with coactivator RIP-140. Mol Endocrinol 13:286–296CrossRefPubMed Peters GA, Khan SA (1999) Estrogen receptor domains E and F: role in dimerization and interaction with coactivator RIP-140. Mol Endocrinol 13:286–296CrossRefPubMed
38.
Zurück zum Zitat Barone I, Cui Y, Herynk MH, Corona-Rodriguez A, Giordano C, Selever J, Beyer A, Ando S, Fuqua SAW (2009) Expression of the K303R estrogen receptor α breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. Cancer Res 69:4724–4732CrossRefPubMedPubMedCentral Barone I, Cui Y, Herynk MH, Corona-Rodriguez A, Giordano C, Selever J, Beyer A, Ando S, Fuqua SAW (2009) Expression of the K303R estrogen receptor α breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. Cancer Res 69:4724–4732CrossRefPubMedPubMedCentral
Metadaten
Titel
A hypersensitive estrogen receptor α mutation that alters dynamic protein interactions
verfasst von
Matthew H. Herynk
Torsten Hopp
Yukun Cui
Airu Niu
Arnoldo Corona-Rodriguez
Suzanne A. W. Fuqua
Publikationsdatum
01.07.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0580-1

Weitere Artikel der Ausgabe 2/2010

Breast Cancer Research and Treatment 2/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.